Clinical Trial Update: Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Phase 2 study of TVB-2640 in MASLD/MASH/NASH has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis
• Metabolic Dysfunction-associated Steatotic Liver Disease
• Non-alcoholic Steatohepatitis

Drugs mentioned

• TVB-2640

Snippet

Sponsor: Sagimet Biosciences Inc. | Conditions: MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | Phase 2 | Status: COMPLETED | Results posted: 2024-12-19